How to Get a GLP-1 Prescription: Who Qualifies, Every Route
To get GLP-1 medicines you need a prescription. Then use insurance, or self-pay from $149 a month (NovoCare Pharmacy: Ozempic pill (from 1.5 mg)).
- Prescription
- Required
- Lowest self-pay
- $149 a month
- Telehealth from, all in
- $223 a month
- Shortage
- Some products short
Half-life and weight loss summary
Half-life in days: how long your body needs to remove half a dose, based on section 12.3 of each FDA label.
Body weight percentage. The trials differ from one another, as do their doses and lengths. Compare each result with the placebo shown on its own page.
Every legitimate way to get GLP-1, ranked
| Route | Who it is for | What you pay |
|---|---|---|
| Ozempic: Novo Nordisk PAP | Household income at or below 200% of the federal poverty level | Free if approved |
| Trulicity: Lilly Cares | Household income at or below 300% of the federal poverty level | Free for up to 12 months |
| For Ozempic: Access through your doctor with insurance plus the savings card | Commercial insurance that covers it | The price may be as low as $25 each month for up to 3 months |
| Through your doctor, get Wegovy with insurance plus the savings card | Commercial insurance that covers it | As little as $25 a month |
| For Mounjaro: Access through your doctor with insurance plus the savings card | Commercial insurance that covers it | With a fill of up to 3 months, the cost can be as little as $25 |
| For Zepbound: Access through your doctor with insurance plus the savings card | Commercial insurance that covers it | With a fill of up to 3 months, the cost can be as little as $25 |
| Through your doctor, get Foundayo with insurance plus the savings card | Commercial insurance that covers it | As little as $25 a month |
| For Rybelsus: Access through your doctor with insurance plus the savings card | Commercial insurance that covers it | A fill covering 1, 2 or 3 months may cost as little as $25 |
| For Trulicity: Access through your doctor with insurance plus the savings card | Commercial insurance that covers it | With a fill of up to 3 months, the cost can be as little as $25 |
Prices checked November 2026. Each price links to its source page.
Sources: Novo Nordisk pricing, NovoCare, TrumpRx, rx.costco.com.
Who qualifies
In the US, every GLP-1 sold needs a prescription. Prescribers write it for a use that the label approves:
- Ozempic: It lowers blood sugar in adults with type 2 diabetes and is used with diet and exercise.
- Ozempic: In adults with type 2 diabetes and heart disease, it lowers the risk of heart attack, stroke, or heart-related death.
- For adults with heart disease and obesity or overweight, Wegovy lowers the risk of heart attack, stroke, or heart-related death in injection and tablet forms.
- Wegovy: For losing weight and keeping it off long term, together with diet and activity. It is for adults and children 12 and older who have obesity, or adults who have overweight and a weight-related condition.
- For adults and children 10 and older with type 2 diabetes, Mounjaro lowers blood sugar. Treatment includes diet and exercise.
- Mounjaro: For high-risk adults with type 2 diabetes, the risk of heart attack, stroke, or heart-related death is lower.
- With diet and activity, Zepbound helps with weight loss and keeping weight off over the long term. Adults who have obesity may use it. It also serves adults who have overweight together with a weight-related condition.
- Zepbound treats obstructive sleep apnea in adults with obesity when the condition is moderate to severe.
- Foundayo is used with diet and activity to lose weight and keep it off over time. It is for adults with obesity, or adults with overweight together with a weight-related condition.
- Rybelsus: It lowers blood sugar in adults with type 2 diabetes and is used with diet and exercise.
- Rybelsus: For high-risk adults with type 2 diabetes, the risk of heart attack, stroke, or heart-related death is lower.
- Trulicity: It lowers blood sugar in adults and children 10 and older with type 2 diabetes. Treatment includes diet and exercise.
- When adults have type 2 diabetes plus heart disease or several heart risk factors, Trulicity lowers the risk of heart attack, stroke, or death tied to the heart.
- Saxenda: Supports weight loss and helps keep it off long term when combined with diet and activity. Children (over 60 kg) who are 12 or older, and adults, can use it for obesity. Adults who have overweight and a weight-related condition can use it too.
- Victoza helps people with type 2 diabetes reduce their blood sugar. It is intended for adults and children aged 10 and older, used alongside diet and exercise.
- Victoza lowers the likelihood of a heart attack, stroke, or heart-related death in adults who have both type 2 diabetes and heart disease.
Source: FDA label (DailyMed).
Comparing telehealth options
| Program | Medicine option | Medicine price | Membership | All in |
|---|---|---|---|---|
| Foundayo pill (self-pay) | $149 a month | $74 a month | $223 a month | |
| Wegovy pill (self-pay) | $149 a month | $74 a month | $223 a month | |
| Ozempic injectable pen (self-pay) | $199 a month | $74 a month | $273 a month | |
| Wegovy pill, starting dose | $149 a month | $149 a month | $298 a month | |
| Foundayo pill, starting dose | $149 a month | $149 a month | $298 a month | |
| Wegovy pill | $149 a month | $149 a month after first month | $298 a month | |
| Ozempic pen | $199 a month | $149 a month after first month | $348 a month | |
| Zepbound (self-pay) | $299 a month | $74 a month | $373 a month | |
| Sesame (Success by Sesame) | Wegovy or Ozempic pen, after intro months | $349 a month | $59 a month | $408 a month |
| Zepbound KwikPen, starting dose | $299 a month | $149 a month | $448 a month | |
| Wegovy pen, 1 mg to 2.4 mg | $349 a month | $149 a month | $498 a month | |
| Zepbound | $1,899 a month | $149 a month after first month | $2,048 a month | |
| Mounjaro | $1,899 a month | $149 a month after first month | $2,048 a month | |
| Compounded semaglutide (not FDA approved) | $60 a month | $79 a month after free first month | $139 a month | |
| Compounded tirzepatide (not FDA approved) | $90 a month | $79 a month after free first month | $169 a month | |
| Compounded liraglutide (daily injection) (not FDA approved) | $179 a month | Not listed | Included | |
| Compounded sublingual semaglutide comes as tablets or drops and has no FDA approval | $179 a month | Not listed | Included | |
| Microdose GLP-1Rx Program (compounded) (not FDA approved) | billed quarterly at $179 a month, starting after the first 4 weeks | Not listed | Included | |
| GLP-1Rx Program (compounded semaglutide) (not FDA approved) | $249 a month, with quarterly billing after the first 4 weeks | Not listed | Included | |
| Compounded GLP-1 plan (not FDA approved) | $99 a month | $169 a month cash | $268 a month | |
| Compounded semaglutide (weekly injection) (not FDA approved) | $297 a month | Not listed | Included | |
| GLP-1Rx Plus Program using compounded GLP-1 with GIP, which has no FDA approval | billed quarterly at $299 a month, starting after the first 4 weeks | Not listed | Included |
Every price listed comes from that program's pricing page. We do not earn money from any of the programs.
| Program | Membership | Type |
|---|---|---|
| $199 a month | insurance-first | |
| $19.99 a month | primary care membership | |
| $79 a month | brand only |
Sources: weightwatchers.com, ro.co, hims.com, sesamecare.com.
Shortage status
Semaglutide: The injection shortage ended on February 21, 2025. Discontinuation of the older Rybelsus tablets is now underway.
| Product | FDA status | Availability |
|---|---|---|
| Rybelsus tablet 3 mg, 7 mg, 14 mg | To Be Discontinued | Replaced by Ozempic (semaglutide) tablets |
- Its first appearance on the FDA shortage list was in March 2022
- Shortage resolved: February 21, 2025
- From April 22, 2025, state pharmacies had to stop making compounded copies
- May 22, 2025 was the date when outsourcing facilities were required to stop
Tirzepatide: The shortage has ended. The FDA confirmed this on December 19, 2024.
- The FDA shortage list first included it on December 15, 2022
- Shortage resolved: December 19, 2024
- State pharmacies had to stop making compounded copies from February 18, 2025
- On March 19, 2025, outsourcing facilities were required to stop
Dulaglutide: Current FDA shortage data does not list it, and Lilly reports that every Trulicity dose is available.
Liraglutide: A current shortage is still listed. Generic products are available, Victoza pens face limited availability, and Saxenda is discontinued in January 2027.
| Product | FDA status | Availability |
|---|---|---|
| Victoza 6 mg/mL pen (2-pack and 3-pack) | Current | Limited Availability |
| Victoza back order | Current | Back order |
| Saxenda 6 mg/mL pen (5-pack) | To Be Discontinued | Available until January 2027 |
| Generic liraglutide (Meitheal, Teva) | Current | Available |
- The FDA shortage list first included it on July 18, 2023
Sources: FDA, api.fda.gov, ashp.org.
Scam signals
- No prescription needed: a seller who skips it is not a licensed US pharmacy.
- Brand pricing far below what the manufacturer charges: the lowest you pay out of pocket for the brand is $149 a month.
- Sold as the brand: FDA has not approved compounded drugs, so none of them are Ozempic, Wegovy, Mounjaro or Zepbound.
- Salt-form warning: the active ingredient in approved drugs is not semaglutide in sodium or acetate salt form.
- Claims of being identical to the brand: telehealth companies received 30 warning letters from the FDA over misleading claims.
- Harm reports: for compounded semaglutide, the FDA lists 990 adverse event reports.
- Harm reports: for compounded tirzepatide, more than 730 adverse event reports are on the FDA list.
- The FTC acted against one program over a monthly price that did not include the drug; see the NextMed review.
Sources: Novo Nordisk pricing, NovoCare, TrumpRx, rx.costco.com.
Find it in your state
- Hims & Hers: Service is not available in all 50 states
- Some of the 50 states do not offer Noom Med
- NovoCare Pharmacy: Delivery reaches each of the 50 states, plus DC, Puerto Rico
Medicaid rules affect the route more than any other factor. weight-loss GLP-1s are covered by 10 state Medicaid programs at present. Select your state to view its drug list and prior authorization rules:
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming